Halozyme Therapeutics Incorporated
Halozyme Therapeutics Incorporate.../ US40637H1095 /
HALO
|
25.09.2024 22:00:00
|
Zm.
-0,3300
|
Wolumen |
Bid00:56:42 |
Ask00:56:42 |
Maksimum |
Minimum |
|
55,8700USD
|
-0,59%
|
1,29 mln
Obrót: 50,8 mln |
55,8700Wolumen Bid: 100 |
56,8400Wolumen Ask: 700 |
56,6650 |
55,4300 |
Opis działalności
Halozyme Therapeutics, Inc. is a platform biopharmaceutical company that researches, develops and markets proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan and worldwide. The company was founded in 1998 and is headquartered in San Diego, California.
Zarząd & Rada nadzorcza
| CEO |
| Helen Torley |
| Zarząd |
| Nicole LaBrosse, Mark Snyder, Michael J. LaBarre, Chris Wahl, Cortney Caudill, Tram Bui, Gary Grote, Amy Fox, Steve Knowles, Christopher Bryant, Kristin Schwartzbauer |
| Rada nadzorcza |
| Jeffrey W. Henderson, Jean-Pierre Bizzari, Barbara Duncan, Matthew L. Posard, Connie L. Matsui, Moni Miyashita, Bernadette Connaughton, Helen Torley |
Dane firmy
| Nazwa: |
Halozyme Therapeutics Inc. |
| Adres: |
12390 El Camino Real,San Diego, CA 92130 |
| Telefon: |
+858 794 8889 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://halozyme.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
- |
